[1]
|
Mok, C.C. (2012) Understanding lupus nephritis: Diagnosis, management, and treatment options. International Journal of Women’s Health, 4, 213-222.
|
[2]
|
Mok, C.C. (2006) Therapeutic options for resistant lupus nephritis. Seminars in Arthritis and Rheumatism, 36, 71-81. http://dx.doi.org/10.1016/j.semarthrit.2006.04.008
|
[3]
|
Bertsias, G., Gordon, C. and Boumpas, D.T. (2008) Clinical trials in systemic lupus erythematosus (SLE): Lessons from the past as we proceed to the future—The EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus, 17, 437-442. http://dx.doi.org/10.1177/0961203308090031
|
[4]
|
Weening, J.J., D’Agati, V.D., Schwartz, M.M., Seshan, S.V., Alpers, C.E., Appel, G.B., Balow, J.E., Bruijn, J.A., Cook, T., Ferrario, F., Fogo, A.B., Ginzler, E.M., Hebert, L., Hill, G., Hill, P., Jennette, J.C., Kong, N.C., Lesavre, P., Lockshin, M., Looi, L.M., Makino, H., Moura, L.A. and Nagata, M. (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Journal of the American Society of Nephrology, 15, 241-250. http://dx.doi.org/10.1097/01.ASN.0000108969.21691.5D
|
[5]
|
Mittal, B., Rennke, H. and Singh, A.K. (2005) The role of kidney biopsy in the management of lupus nephritis. Current Opinion in Nephrology and Hypertension, 14, 1-8. http://dx.doi.org/10.1097/00041552-200501000-00002
|
[6]
|
Sinico, R.A., Radice, A., Ikehata, M., Giammarresi, G., Corace, C., Arrigo, G., Bollini, B. and Li, V.M. (2005) Anti-C1q autoantibodies in lupus nephritis: Prevalence and clinical significance. Annals of the New York Academy of Sciences, 1050, 193-200. http://dx.doi.org/10.1196/annals.1313.020
|
[7]
|
Moroni, G., Radice, A., Giammarresi, G., Quaglini, S., Gallelli, B., Leoni, A., Li Vecchi, M., Messa, P. and Sinico, R.A. (2009) Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Annals of the Rheumatic Diseases, 68, 234-237. http://dx.doi.org/10.1136/ard.2008.094508
|
[8]
|
Swaak, A.J., Groenwold, J. and Bronsveld, W. (1986) Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 45, 359-366. http://dx.doi.org/10.1136/ard.45.5.359
|
[9]
|
Christopher-Stine, L., Siedner, M., Lin, J., Haas, M., Parekh, H., Petri, M. and Fine, D.M. (2007) Renal biopsy in lupus patients with low levels of proteinuria. The Journal of Rheumatology, 34, 332-335.
|
[10]
|
Cameron, J.S. (1999) Lupus nephritis. Journal of the American Society of Nephrology, 10, 413-424.
|
[11]
|
Contreras, G., Pardo, V., Cely, C., Borja, E., Hurtado, A., De La Cuesta, C., Iqbal, K., Lenz, O., Asif, A., Nahar, N., Leclerq, B., Leon, C., Schulman, I., Ramirez-Seijas, F., Paredes, A., Cepero, A., Khan, T., Pachon, F., Tozman, E., Barreto, G., Hoffman, D., Almeida Suarez, M., Busse, J.C., Esquenazi, M., Esquenazi, A., Garcia Mayol, L. and Garcia, E.H. (2005) Factors associated with poor outcomes in patients with lupus nephritis. Lupus, 14, 890-895. http://dx.doi.org/10.1191/0961203305lu2238oa
|
[12]
|
Ruiz Irastorza, G., Espinosa, G., Frutos, M.A., Jimenez Alonso, J., Praga, M., Pallares, L., Rivera, F., Robles Marhuenda, A., Segarra, A. and Quereda, C. (2012) Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.). Nefrologia, 32, 1-35.
|
[13]
|
Mok, C.C. (2010) Biomarkers for lupus nephritis: A critical appraisal. Journal of Biomedicine and Biotechnology, 2010, Article ID: 638413. http://dx.doi.org/10.1155/2010/638413
|
[14]
|
Davidson, A. and Aranow, C. (2006) Pathogenesis and treatment of systemic lupus erythematosus nephritis. Current Opinion in Rheumatology, 18, 468-475.
|
[15]
|
Houssiau, F.A., Vasconcelos, C., D’Cruz, D., Sebastiani, G.D., Garrido Ed Ede, R., Danieli, M.G., Abramovicz, D., Blockmans, D., Mathieu, A., Direskeneli, H., Galeazzi, M., Gul, A., Levy, Y., Petera, P., Popovic, R., Petrovic, R., Sinico, R.A., Cattaneo, R., Font, J., Depresseux, G., Cosyns, J.P. and Cervera, R. (2002) Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis & Rheumatism, 46, 2121-2131. http://dx.doi.org/10.1002/art.10461
|
[16]
|
Illei, G.G., Austin, H.A., Crane, M., Collins, L., Gourley, M.F., Yarboro, C.H., Vaughan, E.M., Kuroiwa, T., Danning, C.L., Steinberg, A.D., Klippel, J.H., Balow, J.E. and Boumpas, D.T. (2001) Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Annals of Internal Medicine, 135, 248-257. http://dx.doi.org/10.7326/0003-4819-135-4-200108210-00009
|
[17]
|
Appel, G.B., Contreras, G., Dooley, M.A., Ginzler, E.M., Isenberg, D., Jayne, D., Li, L.S., Mysler, E., SanchezGuerrero, J., Solomons, N. and Wofsy, D. (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. Journal of the American Society of Nephrology, 20, 1103-1112. http://dx.doi.org/10.1681/ASN.2008101028
|